Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: HTG Molecular, Myriad Genetics, Eclipse Bioinnovations, More

HTG Molecular Diagnostics: HTG Transcriptome Panel 

HTG Molecular Diagnostics has launched its HTG Transcriptome Panel in the US and Europe. The panel is designed to measure approximately 20,000 mRNA targets using the firm's HTG EdgeSeq technology, and is available from the company in kit form or as a service in HTG's VERI/O laboratory. The panel is also currently designed for use with Illumina sequencing platforms. The company said that a recent internal study demonstrated that the FFPE sample input required across five different cancer types (melanoma, lung, breast, prostate, and colorectal) is much less than a typical core needle biopsy and often less than a single FFPE section. The study also revealed that the panel was highly robust and repeatable, and achieved a high accuracy in regard to differential expression. HTG has also commercially released HTG EdgeSeq Reveal version 4.0.0, adding features and software functionalities to support, among other things, data analysis for the HTG Transcriptome Panel. 

Myriad Genetics MyRisk, RiskScore 

Myriad Genetics on Monday launched a new version of its MyRisk Hereditary Cancer test that provides a polygenic risk (PRS) score to all breast cancer patients regardless of their ancestry. The company's MyRisk next-generation sequencing test analyzes 35 genes associated with eight hereditary cancers. Meanwhile, RiskScore, the PRS test, analyzes 140 SNPs that together can enhance the breast cancer risk assessments from MyRisk.  

Since 2017, Myriad has been providing a RiskScore only to women who self-identified as having European and Ashkenazi Jewish ancestry, and who test negative on MyRisk for known high-risk cancer gene mutations. However, the company recently recalibrated RiskScore for all ancestries. "Women who previously took the MyRisk test since 2017 and were unable to benefit from RiskScore due to genetic ancestry, will now be offered the opportunity to have their risk assessment updated by Myriad Genetics free of charge," the company said in a statement.  

With the pan-ancestry PRS added, the company is hoping to provide accurate breast cancer risk assessments to more women. Around 95 percent of women test negative for mutations in genes known to increase their predisposition for cancer, even though they still may be at increased risk for the disease. Now the company estimates that more than half of the patients tested on MyRisk and RiskScore may qualify for increased screening or risk-reducing interventions. 

Eclipse Bioinnovations 3' and 5' End-Seq

Eclipse Bioinnovations has launched its 3' and 5' End-Seq Kits. End-Seq can facilitate the precise identification of untranslated regions (UTR) for RNA therapeutics targeting and can be used as a tool for identifying UTR biomarkers associated with disease. The 3' End-Seq kit can quantify the relative usage of polyadenylation sites across samples while the 5' End-Seq kit can quantify the relative usage of transcription start sites. Both kits can indicate transcript isoform presence in annotated transcriptomes and help predict binding factor motifs more reliably.

For more new products and services, please visit the New Products page on our website.